The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

about

Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis.How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.

P2860

Q50880137-DFC50887-4336-4F29-8339-4CF40DDEA940 Q54939988-406F53E9-42CC-42D8-9011-80772C0CA5E4

P2860

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

Item

http://www.wikidata.org/entity/Q36328066

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

@ast

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

@en

type

Item

label

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

@ast

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

@en

prefLabel

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

@ast

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

@en

P1476

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

@en

P2093

Zelija Velija-Asimi

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for cure of acromegaly: a consensus statement.

Guidelines for acromegaly management.

Guidelines for acromegaly management: an update.

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2042018811434728

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233405525

http://www.w3.org/2001/XMLSchema#string

P698

23148190

http://www.w3.org/2001/XMLSchema#string

P932

3474646

http://www.w3.org/2001/XMLSchema#string

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

about

P2860

P2860

The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932